# The small molecule class IIa HDAC inhibitor TMP269 protects against degeneration in in vitro models of Parkinson's Disease

### O' Mahony AG<sup>1</sup>, Collins LM<sup>1,2</sup>, Sullivan AM<sup>1,3</sup>, O'Keeffe GW<sup>1,3</sup>


## Introduction

Parkinson's disease (PD) is the second most common neurodegenerative disease globally, characterized by midbrain dopaminergic (mDA) neuronal degeneration, leading to progressive motor impairments. The main pathological hallmark of PD is accumulation of the protein  $\alpha$ -synuclein into insoluble aggregates known as Lewy bodies and Lewy neurites. There is no disease modifying therapy for PD, thus identification of new therapies that protect and/or regenerate dopaminergic neurons is essential. Epigenetic modifications, specifically alterations in histone acetylation levels, are associated with the progression of PD pathology. Higher levels of histone acetylation have been reported in mDA neurons of PD patients, when compared to control groups [1]. This has led to consideration of histone deacetylase (HDAC) inhibitors as potential disease modifying therapies targeting histone acetylation. Previous studies by our group have identified the class-IIa HDAC family as targets of interest, reporting neuroprotective effects of specific class-IIa inhibitors on mDA neurons; furthermore, gene co-expression analysis identified the presence of the class-IIa HDACs, HDAC5 and HDAC9, in mDA neurons, making them promising therapeutic targets [2][3].

### Objectives


To assess the therapeutic efficacy of the pharmacological class IIa HDAC inhibitor TMP269 in protecting against degeneration vitro caused by the dopaminergic neurotoxin 6in Hydroxydopamine (6-OHDA) or  $\alpha$ -synuclein-induced neurite injury


## Methods



#### TMP 269 Treatment results in significant increase in neurite length in 6-OHDA-induced degeneration


Results






Data represented as mean +/- SEM as a percentage of the untreated group from *n* = 6 independent experiments., (\*\*p<0.01, \*\*\*p<0.0001, versus untreated control, or as indicated), one-way ANOVA with post-hoc Tukeys's test

#### Delayed TMP269 treatment results in significant increase in neurite length following 6-OHDA-induced degeneration





Data represented as mean +/- SEM as a percentage of the untreated group from n = 3 independent experiments., (\*\*\*p<0.001, \*\*\*\*p<0.0001, versus untreated control, or as indicated) one-way ANOVA with post-hoc Tukey's test

Analyse neurite length of Perform LDH assay on cultured cells collected cellular media


### Conclusion

Pharmacological class IIa HDAC inhibition by TMP269 is protective against both 6-OHDA and  $\alpha$ -synuclein-induced neurite injury

#### [µM TMP269]

[µM TMP269]

#### TMP269 Protects against $\alpha$ -synuclein induced neurite degeneration



Data are presented as mean +/- SEM as a percentage of the untreated group from n = 3 independent experiments, (\*\*p<0.01, \*\*\*p<0.001 versus GFP control group, or as indicated) one-way ANOVA with post-hoc Tukeys's test

Ireland For what's next

#### **References & Affiliations**

I. Department of Anatomy and	[1] Park G, Tan J, Garcia G, Kang Y, Salvesen G, Zhang Z (2015) Regulation of histone acetylation by autophagy in	
	Parkinson disease. J Biol Chem.	
	[2] Collins LM, Adriaanse LJ, Theratile SD, Hegarty SV, Sullivan AM, O'Keeffe GW. 2015. Class-IIa Histone Deacetylase	DEPARTMENT OF ANATOMY & NEUROSCIENCE
ireianu.	Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult. Mol Neurobiol	Neuroscience Science
2. Department of Physiology, University		University College Cork Iroland
College Cork, Ireland.	[3] Mazzocchi M, Wyatt SL, Mercatelli D, Morari M, Morales-Prieto N, Collins LM, Sullivan AM and O'Keeffe GW (2019)	Coláiste na hOllscoile Corcaigh Ireland For what's n
3. Parkinson's Disease Research Cluster	Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as	This work is funded by a Science Foundation Ireland Frontiers for the Future Award
(PDRC), University College Cork, Ireland.	Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling. Front. Cell Dev. Biol.	This work is funded by a science i bandation incland i fontiers for the ratare Awara

Neurite length (%)